FL118 is a novel survivin inhibitor that inhibits cancer stem cell-like properties.FL118 is a novel camptothecin analog with anticancer activity that inhibits epithelial-mesenchymal transition through the Wnt/β-catenin signaling pathway, thereby inhibiting migration and invasion of human breast cancer cells.

FL118 (0-200 nM; 24, 48, and 72 h) suppresses cell proliferation and migration in ES-2 and SK-O-V3 cells, influencing CYGB expression and inhibiting the PI3K/AKT/mTOR pathway, altering vimentin and E-cadherin levels in ovarian cancer cells. FL118 (0-500 nM; 0-72 h) induces dephosphorylation and degradation of DDX5, regulating survivin, McL-1, XIAP, cIAP2, c-Myc, and mKras expression. FL118 (0-1 μM; 24, 48 h) exhibits cytotoxicity against A549, MDA-MB-231, and RM-1 cell lines, enhancing PARP cleavage and triggering apoptosis in A549 cells, primarily arresting them at the G2/M phase.

FL118 (5 and 10 mg/kg; p.o.; once a week; 20 days; female BALB/c nude mice) dose-dependently suppressed ES-2 tumor growth by upregulating CYGB expression.[1] Additionally, FL118 (0-1.5 mg/kg; i.p.; once every other day; five times) effectively eliminated human colon and head-and-neck tumors resistant to irinotecan or topotecan.[4] FL118 (1.5 mg/kg; i.v.; once) also demonstrated favorable pharmacokinetic profiles.[4]